Search PubMed⌕ Search

Biomedical subjects

F Derouin

Publications and source records attributed to F Derouin.

At least 163 records · Page 9Linked to original sources

Sequential determination of IgG subclasses and IgA specific antibodies in primary and reactivating toxoplasmosis.

During the course of T. gondii infection, we have analysed serum IgG and IgA antibodies responses in 50 immunocompetent with acquired infection and 19 immunocompromised patients with evidence of reactivated toxoplasmosis. Using an ELISA, IgG1, IgG2, IgG3 and IgA antibodies were found in sera of all patients, whereas IgG4 antibodies were usually not detectable. In immunocompetent patients, the predominant antibody isotype was IgG1 at the different stages of infection, presumably in relation with a T-cell control of humoral response during toxoplasmosis. In immunocompromised hosts (kidney or bone marrow transplanted and HIV infected patients), a sequential study was performed on serum samples taken before and after reactivation had occurred. The isotypic distribution of antibodies was similar to that observed in immunocompetent patients, but differences between groups of immunocompromised patients were detected when the kinetics of the antibody response was considered. The IgG and IgA antibody rise was lower in HIV1 infected patients with clinical toxoplasmosis; whatever was the peak antibody value, clinical symptoms appeared earlier in patients with a slower antibody response. This presumably reveals a functional T-cell abnormality, which may rely to the defective containment of the parasite in these patients.

Acquired Immunodeficiency Syndrome↗

Toxoplasma infection after human allogeneic bone marrow transplantation: clinical and serological study of 80 patients.

Systematic clinical and serological studies to evaluate the frequency of toxoplasmosis in bone marrow transplant recipients were performed in 80 consecutive patients. Antitoxoplasma antibody titres were measured in donors and recipients before transplant and subsequently post-transplant. Before bone marrow transplant, 54 recipients were seropositive and 26 were seronegative, whereas 35 donors were seropositive and 45 were seronegative. After bone marrow transplant, the frequency of clinical and serological manifestations of toxoplasmosis appeared closely related to the recipient's serological status before transplant. In the seronegative group of patients before transplant the incidence of toxoplasmosis was low: only two patients experienced seroconversion 3 months after bone marrow transplant and one developed clinical symptoms consistent with toxoplasmosis but without cerebral involvement. Clinical toxoplasmosis or secondary elevation of antibody titres was mostly observed in pre-bone marrow transplant seropositive patients; in this group, cerebral toxoplasmosis occurred in four patients and a significant secondary rise of antibody titres was observed in 16 patients. It thus appears that toxoplasmosis is most often related to a reactivation of latent cysts. Prophylactic treatment may be useful in patients presenting serological evidence of past or latent infection before bone marrow transplant.

Adolescent↗

Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement.

In a randomised double-blind study, ivermectin was compared with diethylcarbamazine (DEC) and placebo in the treatment of onchocerciasis in 30 male patients from Mali with moderate to heavy Onchocerca volvulus infections and ocular involvement. 10 patients received a single oral dose of ivermectin, 12 mg, 10 received DEC daily for eight days (total dose 1.3 g), and 10 received matching placebo. Patients were examined periodically for twelve months. Punctate keratitis disappeared in 6 of 7 ivermectin patients but increased in DEC patients. Numbers of O volvulus microfilariae (mf) in the anterior chamber decreased slowly and eventually disappeared in most ivermectin patients during the six months following treatment; anterior chamber mf disappeared more rapidly in some patients after DEC, but reappeared within six months of stopping treatment. Both ivermectin and DEC caused a prompt decrease in mean skin mf density; density then increased in both groups over the twelve month observation period, reaching 9% of pretreatment values in ivermectin patients and 45% in the DEC group. Analysis of adult O volvulus from nodules excised at three and twelve months post treatment showed no effect of either drug on viability; however, there was evidence of degeneration of intra-uterine developing mf in the ivermectin group. Side-effects were less frequent and less severe in ivermectin patients than in DEC patients. Ivermectin as a single oral dose appears to be a more effective microfilaricidal drug than DEC in onchocerciasis.

Adolescent↗

Evaluation of cellular immune response during chronic schistosomiasis in humans by the leukocyte aggregation test and the leukocyte migration inhibition test.

Cellular immune response was evaluated in 31 patients with chronic Schistosoma haematobium and Schistosoma mansoni infections and in 15 healthy normal persons by using S. mansoni soluble worm and egg antigens. Although the leukocyte migration inhibition test demonstrated false-positive reactions, the specificity of the leukocyte aggregation test was confirmed by the negativity of all of the controls. Among the patients, only 10% were positive for the leukocyte aggregation test. This low cellular reactivity was in contrast to markedly elevated specific humoral response determined by an enzyme-linked immunosorbent assay for immunoglobulin G and paper allergosorbent test for immunoglobulin E with soluble worm antigen. These results confirm that the cellular immune reactivity to schistosome antigen as demonstrated by the leukocyte aggregation test is either minimal or absent in chronically infected patients.

Antigens, Helminth↗

IgE response and histamine release in chronic human schistosomiasis.

Total and specific IgE anti-schistosome antibodies were quantitated in 31 patients with chronic schistosomiasis and in 15 controls. Both levels of total and specific IgE were significantly increased in sera of 74 and 68% of infected patients respectively. Histamine release from basophils by specific antigens was assessed using a spectrofluorimetric method. This test was found to be highly significant in all the patients studied. There was a significant correlation between specific IgE levels and histamine release (R = 0.43, p less than 0.05).

Adult↗

[Ecology of a focus of cutaneous leishmaniasis in the Thiès region (Senegal, West Africa). Epidemiologic and clinical characteristics of the human disease].

During their epidemiological survey of a cutaneous leishmaniasis focus, the authors study the epidemiological and clinical aspects of 60 proven human cases observed in the studied area (Thies region). The disease can occur at any age but is more frequently seen in the preadolescent (10-15 years), adolescent (15-20 years) and adult (20-40 years) age classes. During the year, 76.5% of the lesions appear between july and the end of november. The spontaneous evolution of the disease seems to have a one year duration. Less than to lesions are observed in the majority of the cases (91.5%). The lesions are mainly located on upper and/or lower limbs and are generally of humid ulcerated type, often covered by a deep scar; a lymphatic nodular dissemination from a lesion occurs in 25% of the cases.

Adolescent↗

[Ecology of a focus of cutaneous leishmaniasis in the Thiès region (Senegal, West Africa). 4. Spontaneous infestation and biology of Phlebotomus duboscqi Neveu-Lemaire 1906].

Following their epidemiological investigation on the cutaneous leishmaniasis focus of Keur Moussa, the authors study the sandfly fauna. The species Phlebotomus duboscqi is abundant (1,532 samples out of 8,411 sandflies collected between December 1976 and June 1979) and located inside the rodent burrows which have been found to be their larval breeding sites. Five P. duboscqi females out of 356 dissected were infected by Leishmania major promastigotes.

Animals↗

[Binding of fluorescein-labelled lectins on trophozoites and cysts of 3 strains of Toxoplasma gondii].

The presence of carbohydrates on the surface of trophozoites and cysts of Toxoplasma gondii was investigated using 26 fluorescein labelled lectins. Three strains of parasites at different phases were tested; intra-cellular, intra-cystic and free trophozoites did not stain. However Soja hispida lectin intensly bind on cyst wall. The fluorescence could be eliminated by preincubation with certain carbohydrates, but not with trophozoite soluble antigen. These results suggest to the authors that cyst wall may be of host rather than of parasite origin.

Animals↗

[ELISA in schistosomiasis. Limits. Possibility of application (author's transl)].

Sera from patients with schistosomiasis and various infections were examined by an enzyme-linked immunosorbant assay technique (ELISA) using soluble antigens prepared from adult worms and eggs of Schistosoma mansoni. Marked false positive reactions were observed in cases of certain parasitic (hydatidosis) and non parasitic diseases (liver cirrhosis). Equivalent results with the techniques of immunofluorescence and immunoenzymology (done on adult sections) were obtained with adult worm antigen read at a higher optic-density limit. At present, this technique might be useful in seroepidemiological surveys; however, further purification of the antigen will increase its sensibility and specificity.

Echinococcosis↗

Search for Enterocytozoon bieneusi infection in wild monkeys in Cameroon.

Faecal samples collected from 42 wild monkeys in Cameroon were examined for microsporidia by light microscopy (using Weber trichrome and Uvitex 2B stains) and by PCR (using Enterocytozoon bieneusi specific primers). None of the 42 samples was positive, suggesting that wild monkeys do not represent a major reservoir for microsporidia in Central Africa.

Animals↗

Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.

Despite significant antileishmanial activity of amphotericin B (AmB) in vitro, the use of the deoxycholate formulation (Fungizone) is limited because of serious side effects. Lipid formulations of AmB have been proposed to reduce this toxicity. We compared the tolerance and efficacy of the conventional AmB prepared with deoxycholate, AmB emulsified in Intralipid 20%, amphotericin B lipid complex (Abelcet), and liposomal AmB (AmBisome) in a murine model of visceral leishmaniasis induced by Leishmania infantum. Control groups included untreated mice and mice treated with the pentavalent antimonial (Glucan-time). Balb/C mice were infected intravenously on day 0 with 10(7) promastigotes of L. infantum, then treated from days 7 to 17 (early treatment group) or from days 60 to 70 (delayed treatment group). Glucan-time was administered daily by intraperitoneal injection, whereas AmB formulations were administered intravenously on alternate days. On days 20, 60 and 120 in the early treatment group and 72 and 125 in the delayed treatment group, parasite burdens were determined in liver, spleen, and lungs by subculturing using a microtitration method. Abelcet (12 mg/kg) and AmBisome (12 mg/kg) completely eradicated the parasites from the tissues. Both of these lipid formulations enabled higher dosages to be tolerated, and were remarkably more effective than Fungizone (0.8 mg/kg) and AmB diluted in Intralipid 20% (1.2 mg/kg) in the treatment of murine visceral leishmaniasis due to L. infantum.

Amphotericin B↗